Printer Friendly


SAN DIEGO, March 7 /PRNewswire/ -- QUIDEL Corporation (Nasdaq: QDEL) and Glaxo Wellcome plc's wholly-owned subsidiary, Glaxo Group Ltd., today signed a multi-year collaborative heads of agreement for the development of the first rapid point-of-care diagnostic test to detect influenza A and B. Terms of the agreement were not disclosed.

Glaxo Wellcome will promote the benefits of performing point of care influenza diagnostic testing as adjunct to their new anti-viral drug, GG167, for the treatment of influenza, when it is available for sale. The drug is currently in phase II human clinical trials worldwide and has an anticipated filing date for a product license at the end of 1997.

QUIDEL will develop the test incorporating its proprietary QuickVue(R) Generation III one-step technology. The test is designed to aid doctors in the early detection of influenza infections in patients who could then benefit from new anti-viral therapies.

"Our collaboration with QUIDEL is a reflection of our continued commitment to providing the most effective anti-viral therapies for doctors and their patients," said Simon Cartmell, Disease Director for Infectious Diseases at Glaxo Wellcome.

Commenting on the newly signed agreement, QUIDEL President and Chief Executive Officer Steven T. Frankel said, "By combining the strengths of Glaxo Wellcome and QUIDEL, a new paradigm for influenza disease management has been created. This is an important step forward in treating a potentially serious viral disease that affects millions each year.

"We will continue to explore other product opportunities which marry our diagnostic tests to therapeutics for total disease management. This collaboration enhances our established business plan to develop and sell products under QUIDEL brand names and, in line with this strategy, we have retained worldwide product rights with future sales channeled through our present distribution network."

Influenza strains A and B infect tens of millions of people worldwide each year. Additionally, it is estimated that between 10,000 and 40,000 people die annually in the U.S. as a result of pre-existing medical conditions that were exacerbated by influenza infections. Influenza is estimated to cost U.S. consumers $12 billion annually for direct and indirect costs related to medications and lost work time. Through diagnostic testing and early therapeutic intervention, it is hoped that disease progression will be halted or symptoms will be eliminated altogether.

QUIDEL Corporation discovers, develops, manufactures, and markets rapid immunodiagnostic products for point-of-care detection of human medical conditions and illnesses. These products provide accurate and cost-effective diagnoses of acute and chronic conditions in the areas of reproductive and women's health, infectious diseases, allergies and autoimmune disorders. QUIDEL's products are sold to professionals in the physician's office and clinical laboratory, and to consumers through retail drug stores.

NOTE TO EDITORS: Glaxo Wellcome's new drug is named GG167 and is in clinical development for the treatment of influenza. It works by inhibiting production of the neuraminidase enzyme which is responsible for allowing the spread of the flu virus within the body. Unlike a flu vaccine, which is given to prevent infection, GG167 can be given to people already infected by the virus in order to limit or halt the development of flu symptoms.
 -0- 3/7/96

/CONTACT: Steven T. Frankel, President and CEO, 619-552-7902, or Mark Francois, Director, Investor Relations, 619-552-7931, both of QUIDEL; Corrine Gordon, Corporate Communications Executive, Glaxo Wellcome, 011-44-0181-966-8255/


CO: QUIDEL Corporation; Glaxo Wellcome plc; Glaxo Group Ltd. ST: California IN: MTC SU: JVN

ST-MO -- LATH056 -- 1371 03/07/96 18:00 EST
COPYRIGHT 1996 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1996 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 7, 1996

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters